Pathogen Inactivation Technologies The Advent of Pathogen-Reduced Blood Components to Reduce Blood Safety Risk

被引：36
作者：
Devine, Dana V. [1 ,2 ]
Schubert, Peter [1 ,3 ]
机构：
[1] Univ British Columbia, Ctr Blood Res, 2350 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada
[2] Canadian Blood Serv, 1800 Alta Vista Dr, Ottawa, ON K1G 4J5, Canada
[3] Canadian Blood Serv, 2350 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada
来源：
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2016年 / 30卷 / 03期
关键词：
Pathogen inactivation; Pathogen reduction technology; Blood safety; Blood transfusion; FRESH-FROZEN PLASMA; IN-VITRO QUALITY; PLATELET COMPONENTS; ULTRAVIOLET-LIGHT; BACTERIAL-CONTAMINATION; THERAPEUTIC-EFFICACY; APHERESIS PLATELETS; HEPATITIS-B; RIBOFLAVIN; TRANSFUSION;
D O I：
10.1016/j.hoc.2016.01.005
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Pathogen inactivation technologies represent a shift in blood safety from a reactive approach to a proactive protective strategy. Commercially available technologies demonstrate effective killing of most viruses, bacteria, and parasites and are capable of inactivating passenger leukocytes in blood products. The use of pathogen inactivation causes a decrease in the parameters of products that can be readily measured in laboratory assays but that do not seem to cause any alteration in hemostatic effect of plasma or platelet transfusions. Effort needs to be made to further develop these technologies so that the negative quality impact is ameliorated without reducing the pathogen inactivation effectiveness.
引用
收藏
页码：609 / +
页数：10
相关论文
共 54 条
[1]   Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction [J].
AuBuchon, JP ;
Herschel, L ;
Roger, J ;
Taylor, H ;
Whitley, P ;
Li, JZ ;
Edrich, R ;
Goodrich, RP .
TRANSFUSION, 2005, 45 (08) :1335-1341
[2]   Bacterial contamination of blood components [J].
Brecher, ME ;
Hay, SN .
CLINICAL MICROBIOLOGY REVIEWS, 2005, 18 (01) :195-+
[3]   Pathogen reduction technique for fresh-frozen plasma, cryoprecipitate, and plasma fraction minipools prepared in disposable processing bag systems [J].
Burnouf, Thierry ;
Radosevich, Miryana ;
El-Ekiaby, Magdy ;
Goubran, Hadi .
TRANSFUSION, 2011, 51 (02) :446-447
[4]   In vivo viability of stored red blood cells derived from riboflavin plus ultraviolet light-treated whole blood [J].
Cancelas, Jose A. ;
Rugg, Neeta ;
Fletcher, Dana ;
Pratt, P. Gayle ;
Worsham, D. Nicole ;
Dunn, Susan K. ;
Marschner, Susanne ;
Reddy, Heather L. ;
Goodrich, Raymond P. .
TRANSFUSION, 2011, 51 (07) :1460-1468
[5]   Stored red blood cell viability is maintained after treatment with a second-generation S-303 pathogen inactivation process [J].
Cancelas, Jose A. ;
Dumont, Larry J. ;
Rugg, Neeta ;
Szczepiorkowski, Zbigniew M. ;
Herschel, Louis ;
Siegel, Alan ;
Pratt, P. Gayle ;
Worsham, D. Nicole ;
Erickson, Anne ;
Propst, Meisa ;
North, Anne ;
Sherman, Claire D. ;
Mufti, Nina A. ;
Reed, William F. ;
Corash, Laurence .
TRANSFUSION, 2011, 51 (11) :2367-2376
[6]   Pathogen inactivation of Trypanosoma cruzi in plasma and platelet concentrates using riboflavin and ultraviolet light [J].
Cardo, Lisa J. ;
Salata, Jeanne ;
Mendez, Juan ;
Reddy, Heather ;
Goodrich, Raymond .
TRANSFUSION AND APHERESIS SCIENCE, 2007, 37 (02) :131-137
[7]   Pathogen inactivation of Leishmania donovani infantum in plasma and platelet concentrates using riboflavin and ultraviolet light [J].
Cardo, LJ ;
Rentas, FJ ;
Ketchum, L ;
Salata, J ;
Harman, R ;
Melvin, W ;
Weina, PJ ;
Mendez, J ;
Reddy, H ;
Goodrich, R .
VOX SANGUINIS, 2006, 90 (02) :85-91
[8]   A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology [J].
Cazenave, J. -P ;
Follea, G. ;
Bardiaux, L. ;
Boiron, J. -M. ;
Lafeuillade, B. ;
Debost, M. ;
Lioure, B. ;
Harousseau, J. -L. ;
Tabrizi, R. ;
Cahn, J. -Y ;
Michallet, M. ;
Ambruso, D. ;
Schots, R. ;
Tissot, J. -D. ;
Sensebe, L. ;
Kondo, T. ;
McCullough, J. ;
Rebulla, P. ;
Escolar, G. ;
Mintz, P. ;
Heddle, N. M. ;
Goodrich, R. P. ;
Bruhwyler, J. ;
Le, C. ;
Cook, R. J. ;
Stouch, B. .
TRANSFUSION, 2010, 50 (11) :2362-2375
[9]   Preclinical safety profile of plasma prepared using the INTERCEPT Blood System [J].
Ciaravino, V ;
McCullough, T ;
Cimino, G ;
Sullivan, T .
VOX SANGUINIS, 2003, 85 (03) :171-182
[10]   Pharmacokinetic and toxicology assessment of INTERCEPT (S-59 and UVA treated) platelets [J].
Ciaravino, V ;
McCullough, T ;
Dayan, AD .
HUMAN & EXPERIMENTAL TOXICOLOGY, 2001, 20 (10) :533-550
123456